US Executive Officer Management Changes SEC — November 03, 2026

USA Executive & Director Changes

By Gunpowder Editorial ·

42 high priority 42 total filings analysed

Executive Summary

Across the 42 filings in the USA Executive & Director Changes stream (all dated 2026-11-03 window, 41 newly published), the dominant theme is leadership turnover at operating companies alongside board refreshes, with a notable cluster of CFO and CEO transitions (Pfizer, Toast, Concentrix, BGC, Erie Indemnity, Anavex, Phoenix/Enovix).

Financial disclosures embedded in officer-change filings show a mixed picture: Alamar Biosciences grew revenue 68% YoY but widened its net loss, Flywire grew revenue 25% but its Q3 net income was inflated by a ~$39.2M non-recurring tax benefit with gross margins compressing, Chegg revenue fell 40% YoY, and QuidelOrtho revenue fell 12% YoY while cutting full-year EPS guidance. Governance stress is visible in shareholder votes at Regis (all five up-for-election directors failed majority support, with conditional resignations tendered) and in notable say-on-pay dissent at Mercury Systems and QuinStreet. Several filings carry small-cap liquidity or related-party concerns (Picard Medical, Guerrilla RF). Overall, the stream points to management transition risk layered on decelerating or volatile operating trends rather than a single sector shock.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Executive Officer Management Changes SEC digest from November 02, 2026.

Investment Signals (12)

  • Q3 2026 revenue $33.5M up 68% YoY and FY2026 guidance raised to $121-123M (~64% growth at midpoint), but operating loss widened to $15.1M from $7.9M and President Tod White retires at year-end

  • Toast ↓ (BULLISH)
    ▲

    ARR up 24% to $2.5B, Q3 revenue +21% to $1,981M, net income $169M vs $105M, subscription and fintech gross profit +29%; FY2026 guidance raised, but CFO Elena Gomez steps down and Q4 Adjusted EBITDA guide of $200-210M implies a step-down from Q3's $240M

  • Sysco ↓ (BEARISH)
    ▲

    Q1 FY27 GAAP sales +2.8% to $21.7B and adjusted EPS +3.5% to $1.19, FY27 adjusted EPS growth guidance of 9-11% reiterated, but full-year sales growth now expected at the low end of 6-7%; GAAP operating income fell 10.4%

  • Yum China ↓ (BEARISH)
    ▲

    Q3 revenue +8% reported but only +2% ex-F/X, same-store sales -3%, KFC ticket average -5%, core operating profit +6%; net new store target raised to 2,400+ and $1.5B shareholder return on track

  • Chegg ↓ (BEARISH)
    ▲

    Q3 revenue $46.5M down 40% YoY as legacy homework-help wound down; Q4 revenue guided to $38-40M and adjusted EBITDA ~$1M; fully repaid convertible debt with $43.6M cash and investments

  • ▲

    Q3 revenue $619M down 12% YoY, Point of Care -27%; adjusted diluted EPS guidance high end cut from $0.90 to $0.70 and revenue narrowed to $2.52-2.54B; $80M+ cost program targeted for 2027

  • Flywire ↓ (BULLISH)
    ▲

    Revenue +25.1% to $250.3M, TPV +27.7% to $17.8B, Adjusted EBITDA +39.2% with margin up ~310 bps to 32.5%; Q4 guide FX-neutral RLAS growth 14-20% and margin expansion +330 to +530 bps, though gross margin fell YoY (61.0% vs 62.3%)

  • ▲

    Five directors failed majority vote and tendered conditional resignations; say-on-pay against votes 956,752 vs 422,593 for; EVP Company Operations Jamie Suarez departs effective Oct 30 with employment ending Nov 22

  • FY2026 net income attributable fell ~34% to $88.9M (EPS $2.29 vs $3.51) on IPO-related share-based comp, yet quarterly dividend raised ~10% to $0.23 and Fuel50 acquisition completed Sept 30

  • Pfizer ↓ (BULLISH)
    ▲

    Board appointed Cecile Guegan as permanent CFO effective Nov 1 after interim tenure since Aug 16, providing leadership continuity in corporate finance

  • Interim CEO Terrie Kellmeyer made permanent President/CEO and joins board effective Nov 1, citing FDA IND clearance for Fragile X and progress toward a Phase 3 Rett program

  • ▲

    CFO transition from Andre Valentine to Chinnu Susan Varghese effective Dec 1 with Valentine staying through Q2 FY27 for handover, a structured succession that reduces execution risk

Risk Flags (11)

  • All five directors up for election (Alfano, Andrews, Benacci, Lintonsmith, Mansbach) failed majority support and tendered conditional resignations; board must announce decision within 90 days, and say-on-pay drew 956,752 against vs 422,593 for

  • CEO Richard Fang (also Chairman) is funding the company through affiliated loans of ~$1.2M outstanding, including $0.7M at 6% due Feb 28, 2027; the earliest $0.5M of 0% Series II loans are already due because the required $1.0M external funding was not raised

  • Q3 revenue -12% YoY, adjusted EPS high end cut $0.90 to $0.70, nine-month operating cash flow still -$124.0M and GAAP net loss $238.5M; restructuring program underway

  • ▼

    Revenue down 40% YoY with Q4 guided to $38-40M and adjusted EBITDA only ~$1M; management pivoting to inorganic growth while the core homework business keeps declining

  • Operating expenses +81%, Q3 operating loss $15.1M vs $7.9M, nine-month net loss $47.9M vs $22.7M; stock-based comp up to $3.9M from $0.7M; President retirement adds execution risk

  • Same-store sales -3% for both KFC and Pizza Hut, year-to-date -1%, ex-F/X revenue growth only 2% despite headline +8%

  • GAAP operating margin down 48 bps to 3.3%, softer restaurant traffic and higher fuel costs; sales growth guided to low end of 6-7%

  • ▼

    Q3 net income of $74.5M includes ~$39.2M non-recurring tax benefit (incl. $25.2M valuation allowance release); gross margins fell 130-200 bps YoY and director Alex Finkelstein resigned

  • Q4 Adjusted EBITDA guide $200-210M vs Q3 $240M and G&A essentially flat while President/CFO Elena Gomez steps down at year-end

  • Chief Business Officer Kellie Chong departs Nov 13 and a new EVP Sales is installed; company is OTCQX-listed with limited disclosure depth

  • 7,002,993 votes against say-on-pay vs 49,014,946 for, and director Scott Ostfeld received 6,702,156 withheld votes

Opportunities (10)

  • Q4 guidance calls for Adjusted EBITDA margin growth of +330 to +530 bps and FX-neutral RLAS growth of 14-20%; Q3 margin already expanded ~310 bps to 32.5%

  • FY2026 revenue guided to $121-123M, nine-month revenue $89.0M vs $49.2M prior year; the convertible notes remeasurement loss ($9.97M) is flagged as non-recurring, so underlying loss trajectory may ease if revenue scales

  • Permanent CEO appointment following FDA IND clearance for Fragile X and planned Phase 3 Rett program; leadership continuity under the clinical development lead

  • Permanent CFO Cecile Guegan, previously responsible for the biopharma business's financial operations and enterprise integrations, removes interim uncertainty in capital allocation oversight

  • ◆

    Diluted share count fell from 609M to 592M and Q3 diluted EPS rose to $0.29 vs $0.16, with subscription and fintech gross profit growth (29%) outpacing revenue (21%)

  • Quarterly dividend raised ~10% to $0.23 after completing Fuel50 acquisition; Q4 net income up ~34% YoY signals improving run-rate despite FY IPO-related charges

  • Successor with CPA and prior CFO experience at Cognizant joins Nov 9 with a three-week-plus overlap before Dec 1 effective date, limiting transition risk

  • John Sauerland (former Progressive CFO, 35+ years insurance experience) joins board Jan 1, 2027; operating companies rated A by AM Best, Fitch and S&P

  • Kevin Sayer (ex-Dexcom CEO, Dexcom Chairman, former CFO of MiniMed) joins the board; co-CEO PSU awards tied to relative TSR vs S&P 500 align management with shareholders

  • Accendra EVP/COO Perry Bernocchi moves to advisor role through Dec 31 retaining base salary and target 2026 bonus, a low-disruption handoff

Sector Themes (6)

  • Finance and Accounting Leadership Rotation
    ◆

    CFO or principal accounting roles changed at Pfizer (permanent CFO), Toast (Gomez to Senno), Concentrix (Valentine to Varghese), and Willis Towers Watson (Alcock as PAO effective April 1, 2027), with several successors drawn from internal ranks or prior CFO roles; most transitions include overlap periods, suggesting managed rather than distressed succession

  • Board Refresh with Finance and Audit Expertise
    ◆

    Trimble added Matthew Brown (CFO of Tenable, CPA) to Audit Committee; Astec added John Keating (ex-CRH EVP) to Audit Committee; SiriusPoint added Sauerland; FHLB Dallas re-elected and seated new independents, reflecting a sector-wide push for operating and audit credentials

  • Shareholder Dissent on Governance
    ◆

    Regis (majority-vote failure for all five up-for-election directors), Mercury Systems (7.0M against say-on-pay), Autonomix (weakest support on reverse split authority, 110,036 against), and QuinStreet (1.09M say-on-pay against) show pressure on director accountability and compensation design in the current proxy season

  • Revenue Growth Diverging from Operating Quality
    ◆

    Toast, Flywire and Alamar report strong top-line growth, but Flywire gross margin contracted, Alamar operating losses widened, and Yum China headline growth was largely FX-driven; quality-of-earnings scrutiny is warranted on headline figures

  • Cash Flow Strain in Smaller Issuers
    ◆

    Picard Medical related-party borrowing, Guerrilla RF OTC listing and departures, Autonomix reverse split authority, and Alamar convertible notes indicate capital structure stress concentrated in micro and small caps, while large caps (Sysco, Pfizer, Toast) maintain dividends or buybacks

  • Cost Restructuring as a Common Lever
    ◆

    QuidelOrtho launched a program targeting $80M+ annual savings in 2027, Sysco carries Jetro acquisition integration costs, and Phoenix and Flywire show margin-driven earnings focus; management teams are emphasizing efficiency in response to flat or declining organic growth

Watch List (8)

  • Board must publicly announce its decision on conditional director resignations within 90 days of vote certification (Oct 28, 2026 meeting); watch for leadership changes following Andrew Alfano's shareholder engagement

  • $0.5M in 0% related-party loans already due with terms TBD and $0.7M at 6% due Feb 28, 2027; watch for additional funding, dilution, or further insider financing

  • Elena Gomez exits at year-end and Michael Senno assumes CFO on Jan 1, 2027; Q4 Adjusted EBITDA guidance of $200-210M will be the first test of the new finance leadership

  • JP Aubin steps down as Co-CEO effective Dec 31, 2026 and becomes Vice Chairman; watch for further organizational changes and Listed Products/European franchise performance under Abularrage and Windeatt

  • Management signals potential acquisitions of companies with strong IP and customer bases; Q4 2026 results on guidance of $38-40M revenue will indicate runway

  • Varghese joins Nov 9 and becomes CFO Dec 1; Valentine remains through Q2 FY27; watch for any change in guidance or capital allocation signals during handover

  • Interim CEO Brian Bolash appointed Nov 3 after NeCastro's early retirement; watch for permanent CEO appointment announcement from the Nominating and Governance Committee

  • 465,413 target PSUs granted to each co-CEO with relative TSR vs S&P 500 hurdles over 3 and 5 years; new director Kevin Sayer joins board, and watch for any further governance changes

Filing Analyses (42)
QuidelOrtho Corp 8-K mixed materiality 8/10

03-11-2026

QuidelOrtho reported Q3 2026 total revenue of $619 million, down 12% YoY as reported and in constant currency, with Point of Care down 27% on a softer respiratory season and Labs down 6% on China pricing changes. Excluding respiratory, China and U.S. Donor Screening, revenue grew 2%, and Labs and Immunohematology grew outside China. The company also launched a cost transformation and restructuring program targeting over $80 million in annual savings in 2027, and narrowed full-year 2026 guidance, lowering the adjusted diluted EPS range to $0.65-$0.70 from $0.65-$0.90 and revenue to $2.52-$2.54 billion.

  • · Operating cash flow was $20M in Q3 2026, versus -$45.5M a year earlier, but nine-month operating cash flow was still -$124.0M
  • · Nine-month GAAP net loss was $238.5M versus $1,001.1M in the prior-year period, which included a $700.7M goodwill impairment
  • · Adjusted diluted EPS guidance high end was cut from $0.90 to $0.70
  • · Restructuring will reorganize the business into two focused units, Core Diagnostics and Point of Care Diagnostics
  • · Cash and cash equivalents were $166.4M at September 27, 2026, against total borrowings of about $2.94B ($424.4M current plus $2,512.9M long-term)
  • · Current portion of borrowings rose to $424.4M from $178.3M at year-end 2025, a near-term refinancing consideration
INTERNATIONAL FLAVORS & FRAGRANCES INC 8-K neutral materiality 3/10

03-11-2026

International Flavors & Fragrances Inc. (IFF) filed an 8-K under Items 5.02, 5.03, and 9.01 that attaches its amended and restated By-Laws, reflecting amendments adopted as of October 28, 2026. The amendments primarily govern shareholder meeting mechanics, including remote-only or hybrid meetings, special meeting request thresholds (25% of voting stock), timing restrictions, and advance notice and Rule 14a-19 requirements for director nominations. The exhibit contains no financial figures, and the filing does not itself describe any officer or director departure or election.

  • · By-Laws amended as of October 28, 2026 permit annual and special meetings to be held solely by remote communication under Section 602 of the New York Business Corporation Law.
  • · Shareholders holding at least 25% of outstanding voting stock may request a special meeting, subject to exclusions covering the 90-day pre-annual-meeting window, matters similar to those voted within 120 days, and Regulation 14A violations.
  • · Director nominations by shareholders require compliance with advance notice procedures and Rule 14a-19 under the Exchange Act, and proxy access nominations are governed by Section 4 of Article I.
  • · Meeting Proponents must disclose derivative instruments, economic interests, and concert-of-action arrangements in any Request.
Picard Medical, Inc. 8-K negative materiality 7/10

03-11-2026

Picard Medical, Inc. (NYSE American: PMI) appointed Richard Fang, Ph.D., as permanent, full-time Chief Executive Officer effective October 28, 2026, after he served as Interim CEO since June 18, 2026; he remains Chairman of the Board. The appointment involved no change to his $0.4 million annual salary and no new compensation or award. The filing also discloses related-person borrowings from Dr. Fang-affiliated entities, including $0.7 million at 6% interest due February 28, 2027 and $0.5 million at 0% interest, with the earliest of the latter loans already due on terms to be determined because the Company has not received the required $1.0 million of external funding.

  • · Dr. Fang previously served as CEO from September 2021 to July 2023 and has been a Board member since September 2021
  • · Related-party loans from Fang-affiliated entities total approximately $1.2M in outstanding principal
  • · The earliest Series II loans have already become due on payment terms to be determined, as the two-month window passed without $1.0M in external funding
  • · The Company had not received at least $1.0M of external funding as of October 29, 2026
Coeptis Therapeutics Holdings, Inc. 8-K neutral materiality 4/10

03-11-2026

Z Squared Inc. (Nasdaq: ZSQR) elected Jeffery Harris, its Chief Technology Officer, to its Board of Directors effective November 3, 2026, to fill the vacancy left by Michelle Burke's resignation effective May 22, 2026. The Board now has five directors, with three (Adam Sohn, Bryan Fuerst, and Kenneth Cooper) qualifying as independent, so a Board majority remains independent under Nasdaq Rule 5605(b)(1). Mr. Harris will receive no additional director compensation and is not expected to join any Board committee.

  • · Harris is an employee and executive officer, so he is not Nasdaq-independent under Rule 5605(a)(2)
  • · Harris has been CTO since June 24, 2026, after acquisition of Paradox Data, LLC on September 8, 2026 (now a wholly owned subsidiary)
  • · Harris previously served as CEO of Paradox Infrastructure (April 2022 to May 2025) and CEO of Xero Labs (April 2020 to December 2021)
  • · Harris's Executive Employment Agreement dated June 24, 2026, was amended by Amendment No. 1 dated August 24, 2026
  • · Related-party relationships exist with Paradox Infrastructure LLC and Paradox Energy LLC, previously disclosed in 8-Ks filed August 4, 2026 and September 14, 2026
  • · Harris holds an indirect minority interest in Paradox Infrastructure LLC and a 24% membership interest in Paradox Energy LLC
  • · Harris does not currently serve, and has not in the past five years served, as a director of any reporting company or registered investment company
Guerrilla RF, Inc. 8-K mixed materiality 5/10

03-11-2026

Guerrilla RF, Inc. (OTCQX: GUER) appointed Lauren Winslow as Executive Vice President, Sales, reporting to founder and CEO Ryan Pratt, and announced that Chief Business Officer Kellie Chong will depart the company effective November 13, 2026, to pursue other opportunities. The company frames the appointment as part of elevating its leadership team to support growth, while the departure is presented as a planned transition following a two-week handover period.

  • · Kellie Chong's departure is effective November 13, 2026, following a two-week transition period, and she is leaving to pursue other opportunities.
  • · Winslow previously served as Global Vice President of Sales, Transportation at ECI, which was acquired by Rosebank Industries plc for £1.5 billion.
  • · Winslow's prior roles include sales and account management positions at Kalas Manufacturing, Armstrong World Industries, and Bonitz Flooring Group.
  • · Winslow holds a Bachelor of Arts in Communication Studies, summa cum laude, from the University of North Carolina at Greensboro.
  • · Winslow's responsibilities include global sales strategy, oversight of the sales team, key client relationships, and identifying new market opportunities.
Alamar Biosciences, Inc. 8-K mixed materiality 7/10

03-11-2026

Alamar Biosciences reported Q3 2026 total revenue of $33.5 million, up 68% year over year, and raised full-year 2026 revenue guidance to $121 million to $123 million (about 64% growth at the midpoint). However, operating loss widened to $15.1 million from $7.9 million and net loss rose to $13.3 million from $8.0 million as operating expenses grew 81%. President Tod White will retire at year-end 2026 and remain an advisor through June 2027.

  • · Nine-month 2026 revenue of $89.0M versus $49.2M a year earlier, with a nine-month net loss of $47.9M versus $22.7M
  • · Q3 2026 net loss included a $9.97M loss on remeasurement of convertible notes in the nine-month period, a non-recurring item
  • · Stock-based compensation rose to $3.9M in Q3 2026 from $0.7M in Q3 2025
  • · Accumulated deficit reached $216.6M at September 30, 2026
  • · Biopharma customers accounted for the largest share of revenue for the first time, per management
  • · Tod White was promoted to president in October 2025 after joining as CFO and CBO in March 2021 and will advise through June 2027
MERCURY SYSTEMS INC 8-K mixed materiality 4/10

03-11-2026

Mercury Systems' Annual Meeting of Shareholders on October 28, 2026 elected Jean Bua, Gerard J. DeMuro, and Scott Ostfeld as Class II Directors for three-year terms ending in 2029, and shareholders approved all proposals including an advisory say-on-pay vote and the ratification of KPMG LLP as auditor for fiscal 2027. The Board subsequently elected William L. Ballhaus as Chairman and Barry R. Nearhos as Lead Independent Director and set committee composition for the coming year. The say-on-pay approval was more contested, with 7,002,993 votes against versus 49,014,946 for, indicating meaningful shareholder dissent on executive compensation.

  • · Say-on-pay advisory vote received 7,002,993 against votes, a material level of dissent that investors may watch in future compensation discussions
  • · Scott Ostfeld received the lowest director support at 49,338,401 for votes versus 6,702,156 withheld
  • · Chairman and Lead Independent Director roles were filled by the Board on October 28, 2026, separate from the shareholder vote
  • · Scott Ostfeld was assigned to the Human Capital and Compensation Committee and M&A and Finance Committee
Guardant Health, Inc. 8-K neutral materiality 4/10

03-11-2026

Guardant Health's Board approved performance-based restricted stock unit (PSU) awards on November 2, 2026, granting each co-founder and Co-CEO, Helmy Eltoukhy and AmirAli Talasaz, 465,413 target PSUs. Payouts depend on relative total shareholder return versus the S&P 500 over three-year (25% of target) and five-year (75% of target) performance periods, with a 0%–250% payout range and a cap at 100% if absolute TSR is negative. The awards are a compensation arrangement for the Co-CEOs rather than a departure or election of officers.

  • · Payouts are capped at 100% of target if absolute TSR is negative over the applicable period
  • · Unearned 3-Year PSUs below the 55th percentile can carry forward to the five-year period, but only if relative TSR reaches the 75th percentile
  • · Shares from 3-Year PSUs are non-transferable through May 31, 2030; 50% of net after-tax shares from 5-Year PSUs are non-transferable through November 30, 2031
  • · A change in control before May 31, 2027 pro-rates earned PSUs based on elapsed performance period
ELITE PHARMACEUTICALS INC /NV/ 8-K positive materiality 4/10

03-11-2026

Elite Pharmaceuticals (OTCQB: ELTP) expanded its Board of Directors from four to six members on October 28, 2026, unanimously electing Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq., as directors. The filing presents board expansion and new director credentials; it contains no financial results, guidance, or quantitative performance metrics.

  • · Fatmi previously served as Operating EVP of Epic Pharma and CSO of Patheon/Banner Life Sciences, and holds patents in drug delivery technologies.
  • · LaRocca oversaw Y-mAbs' 2025 sale to SERB Pharmaceuticals and previously served as CLO of Actavis and EVP/General Counsel of Eagle Pharmaceuticals.
  • · LaRocca has served as an independent director of BetterLife Pharma Inc. (CSE: BETR) since July 2026.
  • · Elite operates a cGMP and DEA-registered R&D and manufacturing facility in Northvale, NJ.
  • · Chairman Nasrat Hakim stated the new directors will guide the company as it expands its pharmaceutical operations.
BGC Group, Inc. 8-K neutral materiality 6/10

03-11-2026

BGC Group announced that co-CEO JP Aubin will step down as Co-Chief Executive Officer effective December 31, 2026, and assume the role of Vice Chairman, reporting to Co-CEOs John Abularrage and Sean Windeatt. The company states its strategy is unchanged and describes its position as the strongest in its history, though the filing provides no quantitative performance comparison for the period.

  • · Aubin states he worked with Howard Lutnick for twenty years and has over three decades in the industry.
  • · Windeatt credits Aubin with growing BGC's European business and Listed Products business into leading franchises.
  • · BGC and leading global investment banks and market making firms partnered to create FMX, which includes a U.S. interest rate futures exchange, spot FX platform, and the fastest-growing U.S. cash treasuries platform.
SYSCO CORP 8-K mixed materiality 8/10

03-11-2026

Sysco reported first quarter fiscal 2027 results (13 weeks ended September 26, 2026), with GAAP sales up 2.8% to $21.7 billion and adjusted EPS up 3.5% to $1.19, while GAAP operating income fell 10.4% to $717 million due to Jetro Restaurant Depot acquisition-related costs. Management reiterated FY27 adjusted EPS growth guidance of 9%-11%, but full-year sales growth is now expected at the lower end of the 6%-7% range, and results were tempered by softer restaurant foot traffic and higher fuel costs.

  • · Adjusted operating expenses rose 4.0% and International adjusted operating expenses rose 6.3% (7.1% constant currency)
  • · Operating margin contracted 48 bps to 3.3%; adjusted operating margin was flat at 4.3%
  • · Free cash flow of $230 million and cash flow from operations of $278 million were reported for the quarter
  • · Net debt to adjusted EBITDA approximately 2.4x; debt to net earnings approximately 7.7x
  • · Adjusted EPS growth was in line with expectations despite softer restaurant foot traffic and higher-than-expected fuel costs
  • · Lower-than-expected U.S. food cost inflation and a lower industry inflation environment contributed to the reduced sales outlook
  • · Officer change: Kevin Hourican is identified as Chair of the Board and CEO in this release, and Brandon Sewell as CFO, per Item 5.02 disclosure
CHEGG, INC 8-K mixed materiality 8/10

03-11-2026

Chegg reported Q3 2026 total net revenues of $46.5 million, down 40% year-over-year, with a GAAP net loss of $4.7 million and adjusted EBITDA of $5.4 million (12% margin). The company ended the quarter with $43.6 million in cash and investments and fully repaid its remaining convertible debt, while guiding Q4 2026 revenue to $38-40 million, a gross margin of 46-48%, and adjusted EBITDA of about $1 million. The steep revenue decline reflects the wind-down of the legacy homework-help business, and management's growth thesis rests on an employability platform that it expects to contribute more meaningfully in 2027.

  • · Management reports the company has entered a phase of potential inorganic growth, reviewing companies with strong IP and customer bases that could benefit from its employability platform
  • · Legacy homework-help business continued to decline as expected, which is the primary driver of the revenue drop
  • · Language learning product returned to growth in both B2B and B2C channels
  • · Q3 free cash flow of $5.5M was generated while the company fully repaid remaining convertible debt
  • · Management expects the employability business to contribute more meaningfully in 2027
Yum China Holdings, Inc. 8-K mixed materiality 7/10

03-11-2026

Yum China reported unaudited Q3 2026 results with revenue up 8% YoY to $3.5 billion and operating profit up 13% to $451 million, with diluted EPS up 20% to $0.91 (up 12% ex-F/X). However, same-store sales declined 3% reported (97% of prior year level), system sales grew only 3% ex-F/X, and core operating profit grew just 6%, with ex-F/X revenue up only 2%. The company also raised its 2026 net new store target to over 2,400 and is on track to return $1.5 billion to shareholders.

  • · Revenue ex-F/X grew only 2%, while reported growth of 8% was largely currency-driven
  • · Same-store sales declined 3% for both KFC and Pizza Hut, with ticket average down 5% at KFC
  • · Year-to-date same-store sales are down 1% against a prior-year gain of 1%
  • · Diluted EPS ex-F/X growth was 12%, and 8% excluding mark-to-market equity investment impacts
  • · Pizza Hut Company revenue ex-F/X declined 1% YoY in Q3
  • · Dividend of $0.29 per share declared, payable December 22, 2026 (record date December 1, 2026)
  • · Pizza Hut brand acquisition in Mainland China completed August 7, 2026
  • · Pizza Hut operating margin benefited from license fee savings previously payable to Yum! Brands
  • · Officer change flagged in preliminary classification; not detailed in the provided release text
Beacon Financial Corp 8-K neutral materiality 5/10

03-11-2026

Beacon Financial Corporation (BBT) entered into an employment agreement dated October 29, 2026 with Sean A. Gray, effective September 21, 2026, in connection with his appointment as President and Chief Executive Officer of the Company and Beacon Bank & Trust. The agreement provides a $1,000,000 base salary, a target annual bonus of 75% of base salary, annual equity awards with a grant-date fair value of 105% of base salary, and a one-time $275,000 restricted stock award vesting in three equal tranches. Severance terms include two times (or three times following a change in control) the sum of base salary and target bonus, plus equity acceleration and 24 months of benefits continuation.

  • · Employment agreement is effective September 21, 2026, though signed October 29, 2026, indicating a roughly five-week gap between effective date and execution
  • · Severance upon termination without cause or resignation for good reason is two times base salary plus target bonus, increasing to three times if termination occurs within 24 months after a change in control
  • · Severance cash payment is reduced by the value of any accelerated portion of a retention bonus under Mr. Gray's prior employment agreement
  • · Bonus for fiscal 2026 is prorated, combining his prior bonus opportunity (January 1, 2026 to the Effective Date) with the new agreement's opportunity for the remainder of the year
  • · Severance is conditioned on a separation agreement and release becoming effective
  • · Full agreement is filed as Exhibit 10.1 and incorporated by reference
TRIMBLE INC. 8-K neutral materiality 4/10

03-11-2026

Trimble Inc. appointed Matthew C. Brown as a non-employee director effective November 2, 2026, and concurrently as a member of the Audit Committee. Brown is currently CFO of Tenable Holdings (since August 2025) and previously served as CFO of Altair Engineering (January 2021 to March 2025); he is a Certified Public Accountant. The filing discloses standard non-employee director compensation and a planned standard indemnification agreement, with no related party transactions or selection arrangements.

  • · Brown's appointment to the Audit Committee adds a CPA-credentialed finance executive to board oversight of financial reporting.
  • · Director compensation follows the Board of Directors Compensation Policy filed as Exhibit 10.3 to the FY2024 Form 10-K filed April 25, 2025.
  • · No related party transactions under Item 404(a) of Regulation S-K and no selection arrangements were disclosed.
Federal Home Loan Bank of Topeka 8-K neutral materiality 3/10

03-11-2026

FHLBank Topeka announced the results of its 2026 Member and Independent Director elections, electing Lance L. White, Barry J. Lockard, and Bryan D. Cain as Member Directors and Thomas E. Henning as Independent Director, each to four-year terms beginning January 1, 2027 and expiring December 31, 2030. Mr. Henning received 34.3 percent of eligible votes, clearing the 20 percent threshold required for Independent Director election, and Mr. Lockard was deemed elected unopposed in Nebraska after being the sole nominee.

  • · Mr. Henning became a director of FHLBank in 2023; Mr. Lockard in 2019; Mr. White in 2023; Mr. Cain is not a current director
  • · Mr. Lockard was deemed elected on September 25, 2026 as the sole nominee for the Nebraska Member Directorship
  • · Independent Director candidates must be U.S. citizens and bona fide residents of the district; Member Directors must be officers or directors of member institutions meeting minimum capital requirements
  • · Mr. Henning brings experience in auditing and accounting, financial management, project development, law, organizational management, and risk management
  • · Questions may be directed to Matt Koupal at 785.478.8080 or [email protected]
REGIS CORP 8-K negative materiality 7/10

03-11-2026

Regis Corporation disclosed that Executive Vice President, Company Operations Jamie Suarez will leave his officer role effective October 30, 2026, with employment ending November 22, 2026, and severance subject to a release of claims under the company's senior executive severance policy. At the October 28, 2026 Annual Meeting, all five directors who were up for election (Alfano, Andrews, Benacci, Lintonsmith, Mansbach) failed to win a majority of votes cast under the company's majority voting policy and have tendered conditional resignations; the say-on-pay proposal also saw substantially more against votes (956,752) than for (422,593), while the auditor ratification (Grant Thornton LLP) passed comfortably.

  • · Four of six nominees (Alfano, Andrews, Benacci, Lintonsmith, Mansbach – five in total) failed to receive majority support; the board must publicly announce its decision on the offered resignations within 90 days after certification of results
  • · Directors who did not win majority support will recuse themselves from the board's resignation decision, while all directors continue to serve pending that outcome
  • · The company is engaging shareholders, led by new Board Chair Andrew Alfano, to understand the reasons behind the voting decisions
  • · Board and leading proxy advisors recommended in favor of all proposals, including say-on-pay, which still received more against than for votes
  • · Suarez's officer role ends October 30, 2026, but employment continues through November 22, 2026, when severance (subject to release of claims) takes effect
ERIE INDEMNITY CO 8-K neutral materiality 6/10

03-11-2026

Erie Indemnity Company announced that President and CEO Timothy G. NeCastro retired on November 2, 2026, earlier than the previously announced December 31, 2026 date, citing personal reasons. Brian W. Bolash, the Company's Executive Vice President and former Secretary and General Counsel, was appointed Interim President and CEO effective November 3, 2026, and the Board's Nominating and Governance Committee continues its search for a permanent successor.

  • · Bolash has served as Executive Vice President since January 2022 and as Secretary and General Counsel since October 2019
  • · No immediate changes in compensation were made in connection with the transition
  • · No family relationships or Item 404(a) related-party transactions involving Bolash were disclosed
ASTEC INDUSTRIES INC 8-K neutral materiality 3/10

03-11-2026

Astec Industries announced that director Linda Knoll will resign from its Board effective December 14, 2026, after roughly four and a half years of service. The Board has appointed John Keating, former EVP of Americas Materials Solutions at CRH plc with more than 40 years in construction materials, as an independent director effective December 11, 2026, where he will also join the Audit Committee. The transition is a routine board refresh with no financial metrics disclosed.

  • · Knoll's resignation is effective December 14, 2026, while Keating's appointment is effective December 11, 2026, so the two transitions overlap by several days.
  • · Keating transitioned to a senior advisor role at CRH earlier in 2026 after serving as EVP from 2022 to 2026 and holding various positions at CRH and its predecessors from 1994 to 2022.
  • · Keating will be added to the Audit Committee, which is a notable governance assignment for a new director.
Flywire Corp 8-K mixed materiality 7/10

03-11-2026

Flywire reported Q3 2026 revenue up 25.1% YoY to $250.3 million and Total Payment Volume up 27.7% to $17.8 billion, with Adjusted EBITDA up 39.2% to $79.5 million and margin expanding about 310 bps to 32.5%. Q3 net income of $74.5 million was inflated by a roughly $39.2 million non-cash tax benefit (a $22.2 million income tax benefit from $27 million of discrete items, including a $25.2 million valuation allowance release) that management says will not recur. Adjusted Gross Margin fell to 63.7% from 65.7%, and GAAP Gross Margin fell to 61.0% from 62.3%, while the company raised FY2026 guidance and director Alex Finkelstein resigned from the board.

  • · Gross margin and adjusted gross margin both declined YoY (61.0% vs 62.3%; 63.7% vs 65.7%), which the summary does not highlight
  • · Management says the $39.2M tax benefit will not recur and Q3 net income is not indicative of future results
  • · Q4 2026 guidance: FX-neutral Revenue Less Ancillary Services growth 14-20% and Adjusted EBITDA margin growth +330 to +530 bps
  • · FY2026 guidance raised by 2 points at midpoint for revenue growth and 30 bps for Adjusted EBITDA margin growth
  • · Visa assumptions across the big 4 education markets were factored into Q4 outlook
  • · Flywire has not reconciled forecast non-GAAP measures to GAAP figures, citing unpredictable income tax and FX effects
  • · Board change: Alex Finkelstein (Spark Capital, director since 2011) resigned effective October 29, 2026; Sabrina Farmer (ex-Google, GitLab CTO, now leads Microsoft's Commerce Platform) was appointed
  • · Company has a share repurchase program with no expiration; repurchases are constrained by credit facility leverage covenants
FEDERAL NATIONAL MORTGAGE ASSOCIATION FANNIE MAE 8-K neutral materiality 3/10

03-11-2026

Fannie Mae disclosed that Omeed Malik resigned from its Board of Directors, effective October 30, 2026, the date he notified the company. The filing is a brief Item 5.02 disclosure with no stated reason for the resignation, no successor named, and no financial figures.

  • · Resignation effective the same day it was notified to Fannie Mae (October 30, 2026)
  • · Filing dated November 3, 2026, roughly four days after the effective date
  • · No reason for resignation or successor appointment disclosed in the filing
PFIZER INC 8-K positive materiality 6/10

03-11-2026

Pfizer announced that its Board of Directors unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026, having served as interim CFO since August 16, 2026. She will oversee all corporate finance functions, including audit, treasury, investor relations, tax, insurance, OP&A, controllership, and business finance and analytics. The filing contains no period-over-period financial results, so no performance metrics are reported.

  • · Guegan previously was directly responsible for financial operations and reporting of Pfizer's biopharmaceutical business across all therapeutic areas and geographies
  • · Guegan previously led major enterprise acquisitions and integrations and co-led a strategic initiative to identify new sources of growth
  • · Guegan holds a master's degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor's degree in Accounting (French DECF)
  • · Guegan's stated capital allocation focus is disciplined capital allocation alongside targeted investments to drive revenue growth later in the decade
MACROGENICS INC 8-K positive materiality 4/10

03-11-2026

MacroGenics announced the appointment of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors, effective October 30, 2026. Both bring extensive oncology drug development and executive experience, which management says will support the pipeline and long-term strategy. The filing contains no financial results, so no period-over-period performance is reported.

  • · Dr. Kuriakose most recently served as Chief Medical Officer of Terns Pharmaceuticals, which was acquired by Merck in 2026
  • · Dr. Vasconcelles most recently served as Head of Research and Development at Day One Biopharmaceuticals and currently serves as an independent director of Molecular Partners AG and Kura Oncology, Inc.
  • · The filing also references the sale of MacroGenics' CDMO operations and risks related to transitioning those operations to the purchaser
WILLIS TOWERS WATSON PLC 8-K neutral materiality 3/10

03-11-2026

Willis Towers Watson announced that Steven Alcock, 47, will succeed Joseph Kurpis as Principal Accounting Officer and Controller, effective April 1, 2027, following Mr. Kurpis's previously disclosed retirement. Mr. Alcock has been Head of Finance, International since January 2022 and has been CFO of Willis Limited, a regulated U.K. subsidiary, since December 2025, having joined the company in 1997. The filing discloses no arrangements with other persons for his appointment, no family relationships with directors or executive officers, and no material related-party interest.

  • · Mr. Alcock joined the company in 1997 and has held several senior accounting and finance leadership roles before his current positions
  • · Mr. Alcock has served as CFO of Willis Limited, a regulated U.K. subsidiary, since December 2025
  • · No related-party transactions under Item 404(a) of Regulation S-K and no family relationships with directors or executive officers are disclosed
CEA Industries Inc. 8-K positive materiality 4/10

03-11-2026

BNB Standard Corporation (Nasdaq: BNC, formerly CEA Industries) appointed Anthony Scaramucci, founder and Managing Partner of SkyBridge Capital, as an independent director effective November 3, 2026, expanding the Board to seven members. The appointment satisfies the company's obligation under its cooperation agreement with YZi Labs to add an additional independent director. Mr. Scaramucci will host a fireside chat with CEO Alex Odagiu at the SALT Conference in London on November 4, 2026.

  • · Mr. Scaramucci qualifies as an independent director under Nasdaq rules
  • · Appointment fulfills a cooperation agreement obligation with YZi Labs
  • · The company reports it is the world's largest corporate BNB treasury
  • · Filing risk factors flag an open material weakness in internal control over financial reporting, pending litigation over the Asset Management Agreement and unpaid accrued management fees, and collateral obligations under a master loan facility
First American Financial Corp 8-K positive materiality 3/10

03-11-2026

First American Financial Corporation (NYSE: FAF) appointed Darryl D. Button to its board of directors, effective with the November 3, 2026 announcement. Button has been president and CEO of Pacific Mutual Holding Company since April 2022, and previously served as Pacific Life's CFO (2017-2021) and as CFO of Aegon N.V. (2013-2016). The filing discloses no financial results, deal terms, or negative developments.

  • · Button earned a bachelor's degree in mathematics (actuarial science) from the University of Waterloo and is a fellow of the Society of Actuaries and the Canadian Institute of Actuaries
  • · Button previously served as chairman of the board of Transamerica Life Canada and on the executive board of Aegon N.V.
  • · Button is a director of the American Council of Life Insurers and the Leadership Alliance of Orange County
  • · The filing was submitted under Item 5.02 (Departure/Election of Directors or Officers) with Item 9.01 exhibits
Toast, Inc. 8-K mixed materiality 8/10

03-11-2026

Toast reported Q3 2026 results with ARR up 24% to $2.5 billion, revenue of $1,981 million (up from $1,633 million, +21%), and net income of $169 million versus $105 million a year earlier. However, Q3 Adjusted EBITDA growth was strong while the company's G&A was essentially flat ($98 million vs. $102 million, -4%), and President and CFO Elena Gomez will step down at year-end, with Michael Senno succeeding her effective January 1, 2027. Management raised full-year 2026 guidance for Non-GAAP subscription services and fintech gross profit and Adjusted EBITDA, while Q4 Adjusted EBITDA guidance of $200-$210 million implies a sequential step-down from Q3's $240 million.

  • · Gomez will remain as a non-executive advisor through July 2, 2027 to support the transition
  • · Subscription and fintech gross profit growth (29%) outpaced the 21% revenue growth, while the GAAP operating margin on that gross profit reached 26%
  • · Q3 2026 diluted EPS was $0.29 versus $0.16, but diluted share count fell from 609 million to 592 million
  • · Q4 2026 Adjusted EBITDA guidance ($200-$210M) is below the Q3 2026 level of $240M, implying seasonal or sequential pressure
  • · Gomez's departure and the CFO transition are a leadership change with no reported disagreement with the company's financial reporting
Phoenix Education Partners, Inc. 8-K mixed materiality 7/10

03-11-2026

Phoenix Education Partners (NYSE: PXED) reported Q4 FY2026 net revenue of $260.7 million, up from $257.4 million a year earlier, and full-year FY2026 net revenue of $1,017.0 million, up from $1,007.2 million. However, full-year net income attributable to the company fell to $88.9 million ($2.29 diluted EPS) from $133.9 million ($3.51 diluted EPS), largely due to higher share-based compensation tied to the IPO and increased advertising expense. The Board raised the quarterly dividend about 10% to $0.23 per share and the company completed the Fuel50 acquisition on September 30, 2026. The filing also includes an officer-change item (Item 5.02), though the exhibit provided does not detail the specifics.

  • · Net income attributable to PXED fell about 34% for the full year, driven by IPO-related share-based compensation and higher advertising expense, even though Q4 net income rose about 34% YoY.
  • · Full-year adjusted diluted EPS declined slightly to $4.47 from $4.50.
  • · Full-year diluted EPS fell to $2.29 from $3.51, a decline of roughly 35%.
  • · Full-year net revenue growth was only about 1%, with the Q4 increase also roughly flat at about 1.3%.
  • · The FY2027 outlook calls for net revenue of $970.0M to $1,000.0M, which implies a midpoint of about $985.0M and a possible decline from FY2026's $1,017.0M, and adjusted EBITDA of $225.0M to $240.0M versus $249.0M in FY2026. Fuel50 results are included in the outlook.
  • · Fuel50 results are not expected to be material to consolidated results in the near term.
  • · The company had no drawn debt under its $100.0M revolving credit facility as of August 31, 2026; $28.4M of the facility is used by a letter of credit.
  • · The 8-K includes Item 5.02 (officer change) and Item 9.01 (financial statements and exhibits), but the provided exhibit does not describe the officer change; the specifics should be confirmed in the full 8-K body.
QUINSTREET, INC 8-K mixed materiality 4/10

03-11-2026

QuinStreet, Inc. held its 2026 Annual Meeting of Stockholders on October 29, 2026, with 92.75% of the 57,223,392 outstanding shares represented. Stockholders re-elected three Class II directors (Asmau Ahmed, Matthew Glickman, Hillary Smith) to terms expiring at the 2029 annual meeting, ratified PricewaterhouseCoopers LLP as auditor for fiscal 2027, approved non-binding say-on-pay, and approved a 2,164,999-share increase to the 2021 Employee Stock Purchase Plan. Votes on the director elections and say-on-pay show meaningful withheld/against votes alongside strong support, so the outcome is mostly positive with some shareholder dissent.

  • · Glickman received the lowest support of the three nominees, with 2,585,959 votes withheld
  • · Say-on-pay received 1,088,876 votes against, about 2.5% of votes cast
  • · Ratification of PricewaterhouseCoopers received 1,228,462 votes against, and 8,976 abstentions
  • · Filing is dated November 3, 2026 and signed by Chief Legal & Privacy Officer Martin J. Collins
  • · Company headquarters at 950 Tower Lane, Foster City, CA; Nasdaq Global Select Market ticker QNST
SiriusPoint Ltd 8-K positive materiality 4/10

03-11-2026

SiriusPoint Ltd. (NYSE: SPNT) announced that John Sauerland, former Chief Financial Officer of Progressive Insurance with more than 35 years of insurance industry experience, will join its Board of Directors effective January 1, 2027. The appointment adds financial and governance expertise, and the Chair described the addition as strengthening Board perspective. The filing contains no quantitative performance data for the current or prior periods.

  • · Appointment is effective January 1, 2027, roughly two months after the announcement
  • · SiriusPoint's operating companies hold an A financial strength rating from AM Best, Fitch, and S&P, and A3 from Moody's
  • · Mr. Sauerland previously served on the boards of Beazley and FedEx Freight
WOLVERINE WORLD WIDE INC /DE/ 8-K neutral materiality 3/10

03-11-2026

Wolverine World Wide, Inc. (NYSE: WWW) disclosed that Susie Kuhn, President of its Active Group, ceased serving in that role on September 21, 2026, as previously reported. Under a Separation and Release Agreement effective October 31, 2026, Ms. Kuhn will receive one year of base salary in severance, health care continuation benefits, and a prorated FY2026 bonus based on actual company performance, in exchange for a general release and restrictive covenants. This is a departure-related disclosure with no stated change to the company's financial results.

  • · Non-compete restriction runs through October 31, 2027; non-solicitation of employees and customers runs through September 21, 2027
  • · Bonus payment is prorated for FY2026 service and payable only on or after the time active-employee bonuses are paid
  • · Full agreement text will be filed as an exhibit to the Form 10-Q for the period ending October 3, 2026
ACM Research, Inc. 8-K neutral materiality 3/10

03-11-2026

ACM Research, Inc. (ACMR) announced that Yue Ma commenced employment as Chief Operations Officer effective October 1, 2026, under an offer letter dated May 8, 2026 (amended August 24, 2026). Compensation includes a $375,000 base salary, a $100,000 target annual bonus, a $50,000 sign-on bonus, up to $150,000 in relocation benefits, and equity awards of a 100,000-share stock option at $83.58 and 13,470 RSUs granted October 1, 2026. The filing contains no period-over-period financial results.

  • · Yue Ma previously served at ASML as Senior Principal Architect (2014-2023) and Technical Expert (2024-2026)
  • · Yue Ma holds a Bachelor's from University of Texas at Austin and a Doctorate in Chemical Engineering from University of Minnesota Twin Cities
  • · Employment is at will; no family relationships with directors or executive officers; no Item 404(a) related-party interest
  • · Equity awards are subject to Board or Compensation Committee approval
  • · Option vesting: 25% on October 1, 2027, then 36 equal monthly installments
Federal Home Loan Bank of Dallas 8-K neutral materiality 3/10

03-11-2026

The Federal Home Loan Bank of Dallas completed its director election process on October 28, 2026, electing two member directors (Christopher G. Palmer for New Mexico and Max S. Yates for Mississippi) and two independent directors (James D. Goudge and Lorraine Palacios) to four-year terms beginning January 1, 2027. Palmer and Palacios were re-elected, while Goudge, a former member director, moves to an independent seat. Member votes for the two independent seats were 1,948,694 for Goudge and 1,701,243 for Palacios, each well above the 20% threshold required for sole nominees.

  • · Palmer and Palacios have served as directors since January 2023 and were re-elected; Goudge previously served as a member director from April 2014 to December 2025
  • · Committee assignments for Yates and Goudge have not yet been determined, and it is unknown whether Palmer and Palacios will keep their current committee roles in 2027
  • · No open member directorships existed for Arkansas, Louisiana, or Texas in this election cycle
  • · The Bank states no related-party transactions with the elected directors since January 1, 2025, and that member-director-affiliated members receive terms no more favorable than similarly situated members
OWENS & MINOR INC/VA/ 8-K neutral materiality 3/10

03-11-2026

On October 29, 2026, Perry A. Bernocchi, Executive Vice President and Chief Operating Officer of Accendra Health, Inc., entered into a transition agreement under which he will cease to be an executive officer and serve as Strategic Advisor to the CEO until December 31, 2026, unless his employment ends earlier. He keeps his current base salary and remains eligible for his 2026 annual bonus at target, plus severance eligibility under the Officer Severance Policy or change of control agreement, as applicable.

  • · Transition period runs through December 31, 2026, unless employment ends earlier
  • · Bernocchi remains eligible for his 2026 annual bonus at current target
  • · Transition agreement filed as Exhibit 10.1 to the 8-K
  • · Filing is signed by Jonathan A. Leon, EVP and CFO
RING ENERGY, INC. 8-K neutral materiality 3/10

03-11-2026

Ring Energy, Inc. (NYSE American: REI) disclosed that director Richard Harris notified the Board on October 28, 2026 that he is retiring from the Board effective the same day. The filing states his decision was not the result of any dispute or disagreement with the Company regarding its operations, policies, or practices. No financial results or quantitative performance data are included in this filing.

  • · Filing reports Richard Harris's board retirement effective October 28, 2026, the same date he notified the Board
  • · Company explicitly states the retirement was not due to any dispute or disagreement with management on operations, policies, or practices
  • · Common stock (par value $0.001) trades on the NYSE American under symbol REI; company is incorporated in Nevada
  • · Filing dated November 3, 2026 under Item 5.02, signed by CFO Sundip S. Johl
Guardant Health, Inc. 8-K positive materiality 5/10

03-11-2026

Guardant Health (Nasdaq: GH) announced on November 3, 2026 the appointment of Kevin Sayer, former CEO of Dexcom (2015 to 2026) and current Executive Chairman of the Dexcom board, to its board of directors. The company's chairman and co-CEO Helmy Eltoukhy praised Sayer's strategic and operational record in digital health, and Sayer said the company is well positioned to shape the next era of cancer care and disease detection with AI-driven molecular insights. The filing contains no financial results or quantitative performance data.

  • · Sayer served as CEO of Dexcom from 2015 to 2026, Dexcom Chairman since 2018, and a Dexcom director since 2007
  • · Sayer previously served as CFO of Biosensors International, EVP and CFO of Specialty Laboratories, and CFO of MiniMed
  • · Sayer is a Certified Public Accountant (inactive) with a Master's in Accounting and Information Systems and a B.A. from Brigham Young University
Autonomix Medical, Inc. 8-K mixed materiality 5/10

03-11-2026

Autonomix Medical, Inc. (AMIX) held its 2026 annual meeting of stockholders on October 29, 2026, where shareholders approved an amendment to the 2023 Stock Plan increasing authorized shares by 750,000 (to 750,353 total), elected all six board nominees, and ratified Forvis Mazars, LLP as auditor for the year ending March 31, 2027. Stockholders also granted the Board authority to effect a reverse stock split between 1-for-2 and 1-for-25, exercisable before the one-year anniversary of the meeting, though this proposal received the most dissent of the votes shown (110,036 against and 20,313 abstentions alongside 775,257 for).

  • · Approximately 46% of outstanding shares voted, which met the quorum requirement
  • · Director votes withheld ranged from about 9,849 to 12,228 across the six nominees
  • · The 2023 Plan amendment (Proposal 4) drew 39,672 votes against and 5,591 abstentions, with 225,651 in favor, a notably lower approval margin than the other proposals
  • · The reverse split proposal had 3 broker non-votes, while other proposals had broker non-votes near 634,392 on director and plan votes
Optimum Communications, Inc. 8-K neutral materiality 5/10

03-11-2026

Optimum Communications, Inc. (OPTU) expanded its Board of Directors from nine to eleven members on October 28, 2026, appointing Elizabeth Abrams and Daniel Silvers as independent directors. The Board also formed a Special Committee comprising the two new directors to evaluate strategic and financial transactions, including financing, restructuring, reorganization, or recapitalization, and to address potential related-party conflicts of interest. Each new director receives a $75,000 monthly fee under an Independent Director Agreement, plus per diem payments for litigation-related and similar activities.

  • · Special Committee authority extends to reviewing matters involving actual or potential conflicts of interest with current or former directors, officers, equity holders, or management companies
  • · Mr. Silvers' brother is a partner at Ropes & Gray LLP, which the Company retained in the ordinary course for legal services
  • · Per diem supplemental payments apply for days involving mediation, arbitration, depositions, or court appearances (or more than four hours of preparation/negotiation)
  • · Both directors serve until the next annual stockholder meeting and are deemed independent under NYSE and SEC rules
Avantor, Inc. 8-K neutral materiality 3/10

03-11-2026

On October 30, 2026, Avantor's Compensation and Human Resources Committee approved a special long-term incentive award of 62,305 restricted stock units (RSUs) for Executive Vice President, Chief Legal and Compliance Officer and Secretary Claudius Sokenu, recognizing his leadership in litigation and regulatory management, dispute resolution and corporate governance. The RSUs were granted on October 31, 2026 under the 2019 Equity Incentive Plan and vest in equal installments over three years, subject to continued employment. No departure or new appointment is reported; the filing is primarily a compensatory arrangement disclosure.

  • · Grant date was October 31, 2026, one day after committee approval on October 30, 2026
  • · RSU terms are governed by a Form of Restricted Stock Unit Grant Notice filed as Exhibit 10.25 to the FY2025 Form 10-K (filed February 11, 2026)
  • · The award was cited as recognition of litigation and regulatory management, dispute resolution, and corporate governance leadership
Enovix Corp 8-K neutral materiality 4/10

03-11-2026

Enovix Corporation (ENVX) disclosed that Arthi Chakravarthy, Chief Legal Officer and Corporate Secretary, departed the Company effective October 30, 2026. The filing, dated November 3, 2026, is a routine Item 5.02 disclosure and does not describe the reason for the departure or name a successor.

  • · Departure effective date is October 30, 2026, with the report dated November 3, 2026 (Date of earliest event reported: October 30, 2026).
  • · Ryan Benton, Interim Chief Executive Officer, signed the filing, indicating the company is currently under interim CEO leadership.
  • · Filing does not disclose the reason for departure, any severance or separation terms, or a replacement for the CLO and Corporate Secretary roles.
Concentrix Corp 8-K neutral materiality 5/10

03-11-2026

Concentrix Corporation announced that Chinnu Susan Varghese will succeed Andre Valentine as Chief Financial Officer, effective December 1, 2026. Ms. Varghese joins the company on November 9, 2026 to provide a transition period, while Mr. Valentine remains CFO in the near term and is expected to stay through the second quarter of fiscal 2027 to support the handover. The filing discloses no financial performance data, so the announcement is a leadership transition with no reported quantitative impact.

  • · Ms. Varghese, age 42, is a Certified Public Accountant with an MBA from Columbia Business School and a BBA from Pace University
  • · Prior roles include SVP and Group Controller at Marelli (Oct 2024 to Oct 2026), CFO Global Growth Markets at Cognizant (Aug 2023 to Oct 2024), and VP Global Financial Planning and Analysis at Cognizant (Feb 2021 to Aug 2023)
  • · Mr. Valentine is expected to remain with the Company through Q2 fiscal 2027 to provide transition support
ANAVEX LIFE SCIENCES CORP. 8-K positive materiality 6/10

03-11-2026

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., its Interim CEO and SVP of Clinical Development, as President and Chief Executive Officer effective November 1, 2026, and she will also join the Board of Directors. The company cites recent milestones under her interim leadership, including FDA clearance of an IND for Fragile X syndrome and progress toward a planned Phase 3 Rett syndrome program. The filing contains no quantitative financial results, so the announcement is primarily a leadership update with no disclosed negative or flat metrics.

  • · Board appointment was effective November 1, 2026, two days before the November 3, 2026 announcement
  • · Dr. Kellmeyer previously held senior roles at Aardvark Therapeutics, Acer Therapeutics, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Amylin Pharmaceuticals and Gen-Probe
  • · Dr. Kellmeyer holds a Ph.D. in Molecular Biology from SUNY Syracuse and completed a postdoctoral fellowship at the University of Rochester
  • · The Board stated it plans for Dr. Kellmeyer to build a top-notch management team, indicating possible future executive hiring
  • · The company reports active INDs across each of its core indications (Alzheimer's, Rett and Fragile X)

Get daily alerts with 12 investment signals, 11 risk alerts, 10 opportunities and full AI analysis of all 42 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Executive Officer Management Changes SEC

🇺🇸 More from United States

View all →